West Loop Innovations regulatory T cell monoclonal antibody

This asset is an **unnamed preclinical monoclonal antibody program** being advanced through West Loop Innovations in collaboration with the University of Illinois Chicago and Deerfield Management for **autoimmune diseases**. The program is designed to **selectively expand regulatory T cells and sustain their suppressive function**, with the goal of restoring immune homeostasis and providing longer-term control of autoimmunity while avoiding the broad adverse effects associated with generalized immunosuppression. Publicly available information identifies the modality as a monoclonal antibody and the biology as Treg-directed immune modulation, but does **not** disclose a specific antibody name, molecular target, sequence, formulation, route, or manufacturer.

Other names

West Loop Innovations-Regulatory T cells (Tregs)-monoclonal antibody-autoimmune diseasesregulatory T cell monoclonal antibodyTreg monoclonal antibody program